ELAN
Elanco Animal HealthCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Primary-source evidence supports a real earnings improvement: Q1 volumes were strong across pet health and farm animal, management raised 2026 guidance, and the release highlighted accelerating share gains for Credelio Quattro plus blockbuster-scale traction for Zenrelia. Secondary post-print coverage checked here also pointed to constructive analyst follow-through, including target increases from firms such as JPMorgan, Jefferies, and BofA, which is directionally supportive even though full consensus revision data is unavailable.
Posture
Mixed
Lead driver
Sentiment
What changed
3 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Adjusted gross margin declined 40 bps year over year due to farm-animal mix, inflation timing, and higher inventory costs, showing that growth is not fully dropping through yet. [#8-K-2026-05-06]
Momentum
33
Value
61
Sentiment
62
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $27.00 · Bull $31.00 · Bear $21.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $29.46
Why
Momentum33 · Δ7d +11.6
Value61 · Δ7d -0.2
Sentiment62 · Δ7d -7.0
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Lead driver: Sentiment · See AI snapshot
Momentum
33
34% active weight
Current posture
7d trendImproving
Δ7d
+11.6
Δ21d
+4.5
Value
61
32% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
+0.0
Sentiment
62
33% active weight
Current posture
7d trendSoftening
Δ7d
-7.0
Δ21d
-1.5
Why this grade
Composite grade C. Momentum 32.9 / Value 60.7 / Sentiment 62.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$11.82B
Beta
1.87
Shares Out
496.86M
P/E (TTM)
321.8
P/S (TTM)
2.49
P/FCF (TTM)
31.64
Rev YoY
+10.4%
EPS YoY
-109.4%
Gross Margin
+55.0%
Op Margin
+1.3%
Net Debt
$3.85B
Current Ratio
2.40
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology